Apollomics Net Working Capital from 2010 to 2026

APLM Stock   19.00  0.25  1.30%   
Apollomics Net Working Capital yearly trend continues to be very stable with very little volatility. Net Working Capital is likely to drop to about 2.5 M. During the period from 2010 to 2026, Apollomics Net Working Capital quarterly data regression pattern had sample variance of 3741.6 T and median of  145,577,000. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
2.6 M
Current Value
2.5 M
Quarterly Volatility
61.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Apollomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Apollomics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 61.6 K, Interest Expense of 114.2 K or Gross Profit of 216.3 K, as well as many indicators such as Price To Sales Ratio of 49.84, Dividend Yield of 0.0 or PTB Ratio of 1.75. Apollomics financial statements analysis is a perfect complement when working with Apollomics Valuation or Volatility modules.
  
Build AI portfolio with Apollomics Stock
Check out the analysis of Apollomics Correlation against competitors.
Evaluating Apollomics's Net Working Capital across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Apollomics Class A's fundamental strength.

Latest Apollomics' Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of Apollomics Class A over the last few years. It is Apollomics' Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Apollomics' overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

Apollomics Net Working Capital Regression Statistics

Arithmetic Mean103,815,432
Geometric Mean58,529,945
Coefficient Of Variation58.92
Mean Deviation54,044,382
Median145,577,000
Standard Deviation61,168,669
Sample Variance3741.6T
Range143.1M
R-Value(0.85)
Mean Square Error1127.7T
R-Squared0.72
Significance0.000018
Slope(10,260,134)
Total Sum of Squares59865.7T

Apollomics Net Working Capital History

20262.5 M
20252.6 M
20242.9 M
202326.4 M
202243.4 M
202185.8 M

About Apollomics Financial Statements

Apollomics investors utilize fundamental indicators, such as Net Working Capital, to predict how Apollomics Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Working Capital2.6 M2.5 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Apollomics Class A is a strong investment it is important to analyze Apollomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Apollomics' future performance. For an informed investment choice regarding Apollomics Stock, refer to the following important reports:
Check out the analysis of Apollomics Correlation against competitors.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Will Biotechnology sector continue expanding? Could Apollomics diversify its offerings? Factors like these will boost the valuation of Apollomics. If investors know Apollomics will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Apollomics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(52.80)
Revenue Per Share
0.194
Quarterly Revenue Growth
2.623
Return On Assets
(0.75)
Return On Equity
(2.34)
The market value of Apollomics Class A is measured differently than its book value, which is the value of Apollomics that is recorded on the company's balance sheet. Investors also form their own opinion of Apollomics' value that differs from its market value or its book value, called intrinsic value, which is Apollomics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Apollomics' market value can be influenced by many factors that don't directly affect Apollomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Apollomics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Apollomics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Apollomics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.